Small-Molecule Quinolinol Inhibitor Identified Provides Protection against BoNT/A in Mice

Padma Singh, Manglesh Kumar Singh, Dilip Chaudhary, Vinita Chauhan, Pranay Bharadwaj, Apurva Pandey, Nisha Upadhyay, Ram Kumar Dhaked*

Biotechnology Division, Defence Research and Development Establishment, Gwalior, Madhya Pradesh, India

Abstract

Botulinum neurotoxins (BoNTs), etiological agents of the life threatening neuroparalytic disease botulism, are the most toxic substances currently known. The potential for the use as bioweapon makes the development of small-molecule inhibitor against these deadly toxins is a top priority. Currently, there are no approved pharmacological treatments for BoNT intoxication. Although an effective vaccine/immunotherapy is available for immuno-prophylaxis but this cannot reverse the effects of toxin inside neurons. A small-molecule pharmacological intervention, especially one that would be effective against the light chain protease, would be highly desirable. Similarity search was carried out from ChemBridge and NSC libraries to the hit (7-phenyl(8-quinolinylamino)methyl)-8-quinolinol; NSC 84096) to mine its analogs. Several hits obtained were screened for in silico inhibition using AutoDock 4.1 and 19 new molecules selected based on binding energy and Ki. Among these, eleven quinolinol derivatives potently inhibited in vitro endopeptidase activity of botulinum neurotoxin type A light chain (rBoNT/A-LC) on synaptosomes isolated from rat brain which simulate the in vivo system. Five of these inhibitor molecules exhibited IC_{50} values ranging from 3.0 nM to 10.0 μM. NSC 84087 is the most potent inhibitor reported so far, found to be a promising lead for therapeutic development, as it exhibits no toxicity, and is able to protect animals from pre and post challenge of botulinum neurotoxin type A (BoNT/A).

Introduction

Botulinum neurotoxins (BoNTs), produced by Clostridium botulinum, C. baratii and C. butyricum, consist of seven immunologically distinct serotypes (A–G) that are causative agents of a life-threatening neuroparalytic disease known as botulism. The potency, longevity of BoNT intoxication has facilitated use of BoNTs as therapeutic agents [1,2,3,4,5] and the ease with which these toxins can be produced make them potential bioweapons and bioterrorism agents [6,7]. Overdose with BoNT therapeutics can also result in systemic botulism [8]. BoNTs are the only toxin group in the six most dangerous biothreat agents (Category A agents) listed by Centers for Disease Control and Prevention (CDC) (http://www3.niaid.nih.gov/Biodefense/bande_priority.htm). BoNTs are synthesized as ~150-kDa single-chain proteotoxins that are post translationally processed by proteolytic cleavage to form a disulfide-linked dimer, composed of a 100-kDa heavy chain (HC) and a 50-kDa light chain (LC) [9]. The HC comprises a 50-kDa C-terminal domain (HC) that participates in the binding of toxin to productive ectoacceptors on the cell surface of peripheral cholinergic nerve cells [10] and the 50-kDa N-terminal domain (HN) of the HC facilitates the translocation of the LC across an endosomal membrane into the cytosol of the nerve cell [11]. The LCs are zinc metalloendoproteases [3,4,24] that exhibit extraordinary specificities for SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins: SNAP-25, VAMP/synaptobrevin and syntaxin [12,13,14,15]. SNARE proteins are essential for exocytosis of neurotransmitter and cleavage of these protein(s) by BoNT inhibits the release of acetylcholine from synaptic terminals leading to neuromuscular paralysis or botulism [16]. The most effective immunotherapy for protection against BoNTs relies on vaccination with pentavalent toxoid species, although supplies are reserved for high-risk individuals [17]. Moreover vaccination of general public also restricts subsequent BoNT’s therapeutic applications, if needed. There are no therapies available for BoNT mediated post neuronal intoxication. The current treatments for BoNT poisoning are limited to: (i) the administration of antitoxin(s) to neutralize and clear toxin from the circulation which is not effective in post neuronal intoxication [6] and, therefore, would be of limited use following an act of bioterror (as it is likely that victims would seek medical attention only after evocation); and (ii) mechanical ventilation which is necessary once BoNT-induced paralysis compromises thoracic muscle contraction. However, the latter form of treatment would also be impractical, even a limited act of bioterror employing BoNT(s), as critical care resources would likely to be overwhelmed. The estimated cost for treating a botulism patient with such intensive care could be as high as $350,000 [18]. Antibody therapy can be very effective; it has several limitations, including limited availability, lot-to-lot potency, variability and short window of application. Thus, the hypothesis rationalizing a small-molecule-
based therapeutic approach for the treatment of BoNT/A-LC intoxication is as follows: Small drug like molecules can penetrate into the neuronal cytosol and inhibit the toxin’s proteolytic activity during post neuronal intoxication. Alternatively, small-molecule inhibitors of BoNT are sought to antagonize the extracellular or intracellular toxin and can be potentially used to treat pre- and post-exposure. Additionally, if stockpiled in dry, sunlight free, temperature-controlled locations, chemically stable small-molecules would remain viable for many years. In contrast, vaccines possess comparatively shorter shelf-lives. Moreover, with respect to the development of small-molecule therapeutics, the BoNT/A-LC represents a top priority as it possesses the longest duration of activity in the neuronal cytosol in comparison to other BoNT-LCs known to cause botulism in human [5]. Research efforts to identify antagonists against BoNT intoxication have dramatically increased in recent years. However, the discovery and development of BoNT/A small-molecule inhibitors have been a challenging task for researchers since long. Part of the difficulty in this endeavor can be attributed to the unusually large peptide substrate-enzyme interface [19,20] that requires a small-molecule with high affinity to effectively block substrate binding [21]. Also, the BoNT and its domains show considerable conformational flexibility, making design of effective inhibitors complicated. Despite these challenges, a number of papers have been published on the initial steps to discover and develop inhibitors of BoNT/A protease activity using different approaches. Using high throughput screening of the NCI Diversity Set as well as a series of 4-aminoquinolines, Burnett et al. [22] identified several small-molecule inhibitors of BoNT/A from which a common pharmacophore was predicted using molecular modeling [23]. Quinolinol derivatives (QAQ, NSC1010 and others) were reported to inhibit BoNT/A as determined by biochemical, cell and tissue based assay [24]. Mechanism of QAQ binding to BoNT/A-LC and mode of inhibition was studied in detail by Lai et al. [25]. Similarly, a high throughput screening of a library of hydroxamates [26] resulted in the selection of 4-dichlorocinnamic hydroxamate as a lead structure for further development [10]. Gapkova et al. [27] structurally modified 2, 4-dichlorocinnamic acid hydroxamate to improve its potency. On the other hand, a computational screen of 2.5 million compounds resulted in the identification of an inhibitor with a Ki of 12 μM [28], but this value was later invalidated [21]. Computer-aided optimization of this inhibitor resulted in an analog that showed a two-fold improvement in inhibitory potency and displayed competitive kinetics by chelating the active site zinc atom [21].

Though the above approaches have resulted in the identification of a number of small-molecules as BoNT/A inhibitors, no compound has yet advanced to pre-clinical development [24,29,30,31]. The majority of such molecules reportedly demonstrated to be effective in enzymatic assays [21,23,27,28,32,39] and a few small-molecules have been tested in cell-based assays [34,35,36,37]. But the information shows that small-molecules can significantly protect mammals against BoNT/A is scanty [31,36]. We screened the ChemBridge and NSC libraries, consisting of millions of compounds of unknown function for similarity search to 8-hyroxyl quinolinol lead, NSC 94066. Since some of these compounds were commercially available and their functions are currently undefined, we reasoned that novel inhibitors could be identified. Herein we report the effective small-molecule BoNT/A inhibitors with promising in vivo pharmacokinetics. Our results demonstrate that small-molecule can protect mice against pre and post BoNT/A challenge and support pursuit of small-molecule inhibitor as a cost effective alternative for treating botulism and for biodefence measures.

Materials and Methods

1. Expression and Purification of Recombinant BoNT/A-LC Protein

Previously, we have reported the conditions for the high level expression and purification of biologically active light chain protein of botulinum neurotoxin type A from a synthetic gene [30]. In brief, full length BoNT/A-LC gene was cloned in pQE30 vector and expressed in E. coli SG13009 at 21°C for 18 h. The BoNT/A-LC was purified using Ni-NTA agarose and analyzed by 12% SDS-PAGE. The purified protein was characterized by western blotting and MALDI-TOF. The rBoNT/A-LC was dialyzed against 20 mM HEPES (pH 7.4) containing 200 mM NaCl, 10% glycerol (v/v), pH 7.4 and stored at −20°C until used.

2. Assay of rBoNT/A-LC Activity on Synaptosomes

2.1. Preparation of Rat Brain Synaptosomes.

Crude synaptosomes were prepared from rat brain as described by Ferracci et al. [39]. Briefly, fresh rat brain (1 g) was homogenized with a teflon homogenizer in 10 ml of chilled homogenization buffer (0.32 M sucrose, 1 mM PMSE, 1 mM EDTA, and 10 mM HEPES, pH 7.5). Homogenized sample was centrifuged at 10,000 rpm for 15 min at 4°C, and supernatant (~2 mg/ml) was collected and filtered with a 0.22 μ membrane and stored at −20°C.

2.2. Optimization of Assay.

The cleavage reaction was optimized with respect to concentrations of synaptoosome substrate and rBoNT/A-LC, incubation time, and composition of cleavage buffer. Catalytic activity of rBoNT/A-LC protein was performed in 50 μl reaction mixture containing varying concentrations of rat brain synaptosomes and rBoNT/A-LC in reaction buffer (25 mM Tris, 100 mM NaCl, 19.2 mM glycine, 100 μg/ml BSA, 0.1 mM DTT, 10 μM ZnCl2, pH 7.5) and incubated at 37°C. For the time course analysis the reactions were stopped by adding 4× SDS-PAGE sample buffer at 1, 2, 5, 10, 20, 30, 60, 120, 180, 240, 300, 360, 420 and 480 min. The samples were analyzed by western blotting.

3. Molecular Docking Studies

3.1. Preparation of Ligands and Receptor.

The NCI and ChemBridge database libraries were chosen for virtual screening of small-molecule inhibitors on the basis of structure similarity searches. The structures of selected molecules were drawn by Chemsketch (ChemDraw) software (http://www.acdlabs.com) and saved as MDL mol files. The energy minimized pdb files were generated using ArgusLab 4.0.1 (http://www.arguslab.com). Ligand files in the pdb format were opened in AutoDock (4.1) for preparation. Once opened, ligand files were edited and saved in pdbqt format. The three-dimensional structure of BoNT/A-LC (PDB code 3BON) was obtained from the RCSB Protein Data Bank. All water molecules except those which participate in catalysis were removed. The rigid and flexible residues of the protein were selected, and two additional files were created; a file 3BONrigid.pdbqt and file 3BONflex.pdbqt.

3.2. Grid Generation and Running AutoGrid.

AutoDock requires pre-calculated grid maps, one for each atom type present in the ligand being docked. AutoGrid 4.1 was used to create autogrid .gpf, .glg, .fld and map files of atoms for protein. The Grid box was constructed around the active site residue Glu262 which plays a pivotal role in the catalytic activity of BoNT/A endopeptidase [40,41]. The active site residues that surrounded by docking box were Phe163, Glu162, Glu164, Cys165, Lys166, Phe194, Glu224, His227, Arg231, Ala236, Ile237, Pro239, Val258, Ser259, Glu261, Arg363, Tyr366, and Zn(II).
3.3. Preparing the Docking Parameter File and Running AutoDock. The final step in submitting the docking was to run the AutoDock function. To prepare this, the protein's rigid pdbqt file, the flexible pdbqt file and ligand's pdbqt file were specified. At the end of a docking process, the output file '.dlg' showed the docked conformations. These conformations were compared one to another to determine similarities and they were clustered accordingly. The root mean square deviation (RMSD) was used to determine whether two docked conformations are similar enough to be in the same cluster. After that these clusters were ranked from the lowest energy to highest.

4. Screening of Inhibitors using Rat Brain Synaptosome
Test compounds were obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI (Bethesda, MD) and ChemBridge Corporation (San Diego, CA). BoNT/A peptide inhibitor (RRGC) was purchased from Bio Basic (Ontario, Canada). Compounds selected after virtual screening were tested in cleavage-based rBoNT/A-LC enzymatic assay. The inhibitors were dissolved in absolute DMSO and stock solutions were made up to 20 mM.

Initial screening was performed in 40 μl reaction mixture containing 2.05 μg synaptosomes and 6 μM rBoNT/A-LC in cleavage buffer along with the 1 mM small-molecules. For determination of inhibitory molar ratios of small-molecules to rBoNT/A-LC, different concentrations of the small-molecules (100, 200 and 500 μM) and rBoNT/A-LC (25 pM, 200 nM and 6 μM) were used. In control assays, positive control was accomplished without test compound and rBoNT/A-LC and negative control test compound was replaced by DMSO. The incubation was carried out at 37 °C for 15 min. The reactions were stopped by adding 4 × SDS-PAGE sample buffer followed by heating at 100°C for 5 min.

5. Determination of the IC$_{50}$
Fifty-percent inhibitory concentration (IC$_{50}$) values for rBoNT/A-LC were calculated from nine concentrations of compound via dose-response measurements. The reactions were set up in duplicate as described earlier with the decreasing concentrations of inhibitors, keeping the concentration of rBoNT/A-LC constant at 10 nM. Each value is the average of two independent determinations. In all the cases, standard deviations were less than ±20%.

6. Western Blot Analysis
Proteins from catalytic reactions were separated on a 13% SDS-PAGE before transfer to a 0.2 μ nitrocellulose membrane for 60 min at 100 V. After blocking in 5% skim milk/PBS for 2 h at room temperature (RT), the membrane was washed three times for 5 min at room temperature with PBST [2 mM Phosphate buffer (pH 7.4), 137 mM NaCl, 2.7 mM KCl, and 0.1% Tween 20(v/v)]. Rabbit anti-SNAP-25 antibody against N-terminal SNAP-25 protein (Sigma, USA) was added at the dilution of 1:5000 in PBS and the blot was incubated for 1 h at RT and washed four times with PBST. Goat anti-rabbit HRP conjugate antibody at a dilution of 1:30000 into PBS was added and further incubated for 1 h at RT. Membrane was again washed with PBST four times, each of 10 min. Bound antibodies were detected by chemiluminescence using an ECL western blot kit (Biological Industry, Israel) as per manufacturer's instructions. Film was exposed for 15 s before development. The inhibitory action (%) of the molecules was evaluated by densitometric analysis of blots using GS800 densitometer and Quantity One software (BioRad, USA).

7. Evaluation of Small-molecule Inhibitors in Mouse Model
Four inhibitor molecules were selected for in vivo experiment based on in vitro results. Female Balb/c mice (20–25 g weight) were used for in vivo experiments and they were divided into seventeen groups having five mice each (four groups for each molecule and one group for BoNT/A control). Mice from one group received 5 LD$_{50}$ of BoNT/A (in 200 μl PBS) intraperitoneally (ip). All four compounds were tested using four groups of mice as described below. To determine the toxicity of compounds, each of the molecule (1 mM) solubilized in PBS/DMSO (9:1) was injected per mouse ip in second group. In third group, 100 μl (1 mM) of small-molecule inhibitor mixed with 5 LD$_{50}$ of BoNT/A holotoxin was injected ip. Fourth group received 5 LD$_{50}$ of BoNT/A, 30 min before the inhibitor injection. In last group of animal (fifth group) 100 μl each (1 mM) of small-molecules were injected 30 min prior to challenge with 5 LD$_{50}$ of BoNT/A. All mice were examined for 4 days at hourly interval for survival, behavior, breath, and extraocular symptoms of botulism. All the animal experiments were approved by the Laboratory Ethical Committee on Animal Experimentation of Defence Research and Development Establishment, Gwalior, India via permission no. BT/01//DRDE/2009 and all efforts were made to minimize suffering.

Results and Discussion
In the wake of the events of September 11, 2001, research efforts aimed at the discovery of potent antagonists for agents of bioterrorism have increased exponentially. However, despite the plethora of new data that has emerged in the past 5 years, an established pharmacophore validated through in vivo models of exposure remains elusive. Indeed, in the case of BoNT, few studies have reported the assessment of any small-molecule antagonist in animal models [31,36]. The development of small-molecule inhibitors as intraneuronal therapeutics is a crucial unmet need. Our initial impetus for producing recombinant LC as a reagent to be utilized in synaptosome based assay for the screening of potential inhibitors of the BoNT/A-LC protease activity. A 1401 bp DNA fragment encoding BoNT/A-LC along with 14 amino acids of translocation domain and 15 amino acids of N-terminal heavy chain was selected to produce rBoNT/A-LC as already reported in our previous study [38].

1. Strategy and Virtual Screening
We focused on serotype A since it is the most prevalent and well-studied among the various serotypes in human intoxication. We used in silico screening to identify BoNT/A inhibitors. The ChemBridge and NSC libraries, consisting of millions of compounds of unknown function, were chosen for virtual screening to chemoinformatically “mine” novel small-molecule non-peptidic inhibitors (SMNPIs). Since some of these compounds were commercially available and their functions currently undefined, we reasoned that novel inhibitors could be identified.

Peptidomimetics and hydroxamic acid-based inhibitors have been developed that display inhibitory effects in the high nM range for the light chain of the BoNT serotype A (BoNT/A -LC) [26,34,35,40,42,43]. Compounds that contain zinc-coordinating sulfhydryl moieties might potentially inhibit host zinc proteases thereby making them poor therapeutic leads. The characteristically poor pharmacokinetics of hydroxamates, their instability, and their reported toxicity, which is likely due to their inhibition of an
array of metalloproteases, also make them problematic as therapeutic agents [44,45]. We focused on the 8-hydroxy quinolinol lead NSC 84096 for database search. Selection of this compound was based on: (i) NSC 84096 is reported to be very potent and serotype A selective inhibitors [24]; (ii) it is reported to be non toxic and active in cell based and mouse phrenic nerve hemi-diaphragm (MPNHD) assays [24]; (iii) there are quinolinos in clinical trials for Alzheimer’s disease and cancer [46–48]; and (iv) quinolinol-based drugs such as linolept and vioform (generic name: Clioquinol) are available in the market. The compounds from the NCI database were docked into the active site in one of the three dimensional structure of BoNT/A-LC (PDB code: 3BON) [41] after removing the peptide occupying the active site. The top scoring 100 compounds were evaluated in detail; the list was narrowed to 25 compounds (based on binding energy and Kᵢ) that interacted well with the active site Zn and demonstrated a ‘good fit’ in the BoNT/A-LC binding site (Table S1). Among these, twelve compounds were studied in detail and in silico parameters obtained were summarized in table 1. Other thirteen molecules were not available for the in vitro and in vivo studies.

The particular class of quinolinol identified in our study is reported to specifically inhibit BoNT serotype A and does not inhibit simply by chelating active-site zinc. The structures of the quinolinol derivatives under investigation contain additional basic moieties including 2-amino or 3-amino pyridine (Table S1). The presence of these structural motifs suggests that these molecules may interact with the hydrophobic pocket located in the active site of the BoNT/A-LC and interact with Tyr366 and Val258. The quinolinol moiety alone in the presence of zinc does not inhibit the proteolytic activity of BoNT serotypes A and B as described by Adler et al. [49]. Data obtained from in silico docking along with the in vitro inhibition at 100 μM concentration of quinolinol derivatives used in the study is summarized in table S2. As shown in figure 1, NSC 84087 is docked in the large hydrophobic pocket of the BoNT/A-LC active site, and its hydroxy quinoline moiety coordinates with zinc. The methoxy group of aniline ring can form a hydrogen bond with His227, which coordinates with zinc, and may contribute to the specificity and potency of this inhibitor. Additionally, the phenyl group is found to fit between Glu164 and Cys165 which are reported to participate in substrate binding [40]. This could explain the importance of hydroxy group in inhibiting BoNT/A-LC, and suggests that the quinolinos inhibit BoNT/A by blocking the active site zinc. It should be noted that the crystal structures of the complexes of known small-molecule and peptide inhibitors with BoNT/A-LC have shown that chelation to zinc is involved in the binding and inhibition of the light chain in both cases [40,41].

2. Inhibition of rBoNT/A-LC using Synaptosome Model

BoNT-LCs are remarkable among proteases for the extremely long substrate required for efficient proteolysis, whereas other microbial metalloproteases have been found to display activity against as short as dipeptides [50]. The catalytic LC domain of BoNT/A is a compact globule consisting of a mixture of ɑ-helices, β-sheets, and ɑ-strands with a zinc-containing metalloprotease active site bound deeply inside a large open cavity [19]. The remarkable substrate selectivity of BoNT/A for SNAP-25 has been explained to be a consequence of extensive interactions with two exosite domains distinct from the active site [51]. A model for substrate recognition has been proposed in which ɑ-exosite binding occurs first via helix formation in the appropriate region of SNAP-25, followed by ɑ-exosite recognition and subsequent conformational changes in the enzyme to facilitate efficient substrate cleavage [19]. This model argues that, without exosite

| S | No | Compound ID      | Binding energy (Kᵢ) (nM) | Interaction energy Electrostatic energy | Vdw_hb_desolv energy | Torso_hb energy | Total internal energy | RMS Ref | Torsional energy | TVdW energy | TSigma energy |
|---|---|-----------------|--------------------------|----------------------------------------|----------------------|-----------------|---------------------|--------|-----------------|-------------|---------------|
| 1 | 1 | CB6377128       | 538.9 pm                 | 7.18                                   | 2.84                 | 1.37            | 14.89               | 1.37   | 2.57            | 3.05        | 0.06          |
| 2 | 2 | CB7969312       | 28.3 pm                  | 8.66                                   | 2.78                 | 1.92            | 11.79               | 1.92   | 2.05            | 3.18        | 0.11          |
| 3 | 3 | CB7967495       | 4.26 pm                  | 6.75                                   | 2.3                   | 1.55            | 18.42               | 1.55   | 2.14            | 3.0         | 0.03          |
| 4 | 4 | CB79574939      | 4.26 pm                  | 6.72                                   | 2.13                 | 1.23            | 19.46               | 1.23   | 1.92            | 3.6         | 0.12          |
| 5 | 5 | CB79587355      | 6.07 pm                  | 6.41                                   | 3.47                 | 1.92            | 12.04               | 1.92   | 1.92            | 4.1         | 0.05          |
| 6 | 6 | CB7976265       | 2.26 pm                  | 6.36                                   | 3.18                 | 1.37            | 17.13               | 1.37   | 1.11            | 4.6         | 0.04          |
| 7 | 7 | NSC1010         | 22.36 pm                 | 7.06                                   | 2.05                 | 1.23            | 18.05               | 1.23   | 1.88            | 5.3         | 0.07          |
| 8 | 8 | NSC84090        | 2.11 pm                  | 6.7                                   | 2.23                 | 1.11            | 13.56               | 1.11   | 1.11            | 4.6         | 0.06          |
| 9 | 9 | NSC84096        | 25.09 pm                 | 6.7                                   | 3.05                 | 1.37            | 12.87               | 1.37   | 1.37            | 6.7         | 0.03          |
| 10| 10| NSC84087        | 52.86 pm                 | 6.7                                   | 3.18                 | 1.11            | 12.87               | 1.11   | 1.11            | 6.7         | 0.04          |
| 11| 11| NSC84089        | 85.36 pm                 | 6.7                                   | 3.18                 | 1.11            | 12.87               | 1.11   | 1.11            | 6.7         | 0.04          |
| 12| 12| NSC84098        | 160.1 pm                 | 6.7                                   | 3.18                 | 1.11            | 12.87               | 1.11   | 1.11            | 6.7         | 0.04          |
binding, BoNT/A-LC is a significantly less efficient enzyme, and thus these regions could be targeted for lead development. BoNT/A-LC requires a minimal SNAP-25 peptide sequence of ~51 amino acids to achieve efficient cleavage, and optimal binding occurs with only the full length SNAP-25 [50]. The crystal structure of SNAP-25 (residues 141–204) bound to BoNT/A-LC (residues 2–420 with active site mutations E224Q, Y366F) provides an explanation for this finding as binding involves protein exozymes that anchor the substrate and position the scissile bond for cleavage [19]. BoNT/A-LC recognizes multiple sites within SNAP-25; an extended surface on SNAP-25 distanced from the site of cleavage [19,50] and residues adjacent to the scissile bond that are discontinuous and appear as pockets surrounding the cleavage site [51]. This implicates multistep recognition of SNAP-25 for cleavage by BoNT/A-LC. Intracellular BoNT/A-LC is shown to directly bind SNAP-25 on the plasma membrane.

Figure 1. Binding mode of NSC84087 into BoNT/A-LC substrate binding cleft showing ligand (grey) interacting with Zn atom (green) and other amino acids (ie HIS 227, GLU 164 and GLU 262).

doi:10.1371/journal.pone.0047110.g001

The LC of BoNT/A specifically cleaves the C-terminal 9 amino acids residues of SNAP-25, between residues Glu197 and Arg198 of the 206, thereby producing a 24 kDa cleaved protein [12]. Analytical techniques have been developed that directly assess SNAP-25 cleavage in cell lysates by immunoelectrophoresis [39]. We analyzed the amount of intact versus cleaved SNAP-25 using monoclonal antibodies against SNAP-25. The selected compounds were initially screened for inhibition of rBoNT/A-LC mediated cleavage of synaptosomal SNAP-25 isolated from rat. NSC 84090 and Tetra peptide inhibitor RRGC-LC (200 nM). From this experiment seven new lead analogs (CB796312, CB7925339, CB7887535, CB6378306, CB6376015, and NSC84096) showed decrease in inhibition (37 and 85% respectively) of endopeptidase cleavage of SNAP 25 using the same concentrations of rBoNT/A-LC (200 nM). This indicates that 50% BoNT/A-LC inhibition is achieved when the inhibitor: rBoNT/A-LC molar ratio is 4:1; however 100% inhibition was recorded at 6:1 molar ratio. In addition, the IC50 values of the compounds increased (worsened) 4- to over 50-fold when the concentration of one of the model enzymes, β-lactamase, was increased 10-fold, from 1 nM to 10 nM [54]. The authors also suggested for the unifying mechanism to be followed for the discovery of the inhibitors.

Identification of SMNPI against BoNT/A in Mice

Major advantages of a synaptosome based assay are: (i) it provides full length SNAP-25 substrate to β-exosite recognition and subsequent conformational changes in the enzyme to facilitate efficient substrate cleavage. It has been considered that, without exosite binding, BoNT/A is a significantly less efficient enzyme; and (ii) it simulates the microenvironment of the neurons. The other advantages are considerable reduction in the number of animals used (millions of reactions can be performed from synaptosomes isolated from single rat brain), substrate stability (synaptosomes isolated are stable for use as substrate for more than year), instrumentation requirement and cost incurred, especially when used for assessing large numbers of target molecules. We suspect the use of small peptide substrates (~17mer peptides/fluorescent substrate which is minimum substrate required for BoNT/A) in high-throughput screening and identification of small-molecule inhibitors is the reason for in vitro and in vivo disconnect which is reported by Eubanks et al. [36]. In majoritity of such studies carried out for the development of small-
molecule inhibitors against botulinum neurotoxins, higher potency of small-molecule inhibitors observed during evaluation in the in vitro assay systems using small peptide substrate, may have resulted due to the suboptimal activity of BoNT/A-LC. As these small substrate peptides used for in vitro screens are not long enough to simultaneously occupy cleavage site and either of the exosite, hence it is clear inhibition in fluorescent peptides based assays relies on the interactions in the enzyme active site. However, our findings argue that in the context of BoNT therapeutics, caution should be used in extrapolating in vivo potency from these assays.

3. Evaluation of Small-molecule Inhibitors in Mouse Model

To be useful as therapeutics, the newly identified inhibitors must: (i) be able to enter neurons; (ii) inhibit the toxin within the neuronal cytosol; and (iii) be tolerated by animals (i.e. possess acceptable toxicity profiles). A true test or ultimate goal for inhibitors evaluated in both cell-free systems and even for cell based assays is whether their effectiveness holds true in vivo. The effectiveness of small-molecule inhibitors in the in vitro and ex vivo assays was only demonstrated when the compound was premixed with BoNT/A; thus far, pre-loading the inhibitor did not protect cells/tissues against BoNT intoxication [24]. The small-molecule inhibitor that was reported to be active in primary neurons [22] was demonstrated to show a dose-dependent inhibition of SNAP-25 cleavage in a non-pre-loading system (cells were pretreated with inhibitor for 45 minutes followed by incubation with BoNT/A in the continuous presence of inhibitor). Additionally, the inhibitors reported by Eubanks et al. [36] and Boldt et al. [34] were characterized in cell culture assays that involved mixing BoNT/A toxin and varying concentrations of inhibitor. To our knowledge, no group has been able to provide experimental evidence showing that their inhibitors work in a pre-loading system.

After completion of our in vitro screening, three compounds were deemed to have suitable activity and were advanced into animal models (CB 7887535, CB6378306 and NSC 84087). The fourth compound, included for comparison, was a molecule previously well characterized and reported to inhibit specifically BoNT/A-LC (NSC 1010). To examine the lead compounds in vivo, a well-established mouse bioassay was used. This model is the Food and Drug Administration (FDA) standard for assessing BoNT levels and the universally accepted method for the study of BoNT antagonists (e.g., antibodies, small-molecules) [55]. For evaluation of inhibitory potential of small-molecules, they were injected into test animals as described in materials and methods. All animals were monitored continuously for a period of 4 days for signs of botulism, and the time of death was recorded. Of the compounds studied, one compound (NSC 84087) showed efficacy in preventing BoNT/A-induced death in all three modes of injections and an injection dosage of 100 μM per animal survived the BoNT challenge with no obvious signs of botulism up to 48 h (Fig. 5). All the mice of inhibitor followed by BoNT/A group, showed symptoms after 20 h and died within 30 h of injection. Mice of other two groups, BoNT/A followed by inhibitors and inhibitors toxin premixed, survived up to 48 h. In similar in vivo studies, conducted by Eubanks et al. [36] and Pang et al. [31] reported mere 36% increase time to death and 10% of mice survival after...
days of standard observation period, respectively. The second compound CB 7887535 extended the time to death from ~9 to ~20 h, corresponding to a more than 100% increase in time to death. Although this appears modest at first glance but this enhancement is also remarkable considering potency of the neurotoxin. In contrast, animals treated with NSC 1010 and CB6378306 molecules at similar doses died without any statistically significant increase in the time to death relative to control group (between 8–10 h). In all cases, no toxicity was observed from treatment with either inhibitor compound alone.

References

1. Bhidayasiri R, Truong DD (2003) Expanding use of botulinum toxin. J Neurol Sci 235:1–9.
2. Carruthers A, Carruthers J (2008) Botulinum Toxin Products Overview. Skin Therapy Lett 13:1–4.
3. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, et al. (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting typeABasis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278:1363–1371.
4. Mahajan ST, Bruhaker L (2007) Botulinum toxin: from life-threatening disease to novel medical therapy. Am J Obstet Gynecol 196:7–15.
5. Poulain B, Popoff MR, Molgo J (2008) How do the Botulinum Neurotoxins block neurotransmitter release: from botulinum to the molecular mechanism of action. The Botulinum J 1:14–87.
6. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070.
7. Josko D (2004) Botulin toxin: a weapon in terrorism. Clin Lab Sci 17:30–34.
8. Crownover BE, Brunstrom JE, Recette BA (2007) Iatrogenic botulism due to therapeutic botulinum toxin A injection in pediatric patient. Clin Neuropharmacol 30:310–313.
9. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898–902.
10. Black JD, Dolly JO (1996) Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 135:535–544.
11. Montal MS, Blewitt T, Tomich JM, Montal M (1992) Identification of an iron channel-forming motif in the primary structure of tetanus and botulinum neurotoxins. FEBS Lett 313:12–18.
12. Binz T, Blasi J, Yamazaki S, Baumeister A, Link F, et al. (1994) Proteolysis of SNAP-25 by type E and A botulinum neurotoxins. J Biol Chem 269:1617–1620.
13. Schiavo G, Stone CC, Bennett MKZ, Scheller RK, Montecucco C (1995) Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxin. J Biol Chem 270:10566–10570.
14. Schiavo G, Benfenati F, Poulain B, Rossetto O, DeLaureto PP, et al. (1992) Tetanus and botulinum B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832–835.
15. Yamazaki, Baumeister SA, Binz T, Blasi J, Link F, et al. (1994) Cleavage of members of synaptobrevin/VAMP family by types D and F botulinum neurotoxins and tetanus toxin. J Biochem 269:12764–12772.
16. Montecucco C, Schiavo G (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13:1–8.
17. Byrne MP, Smith LA (2000) Development of vaccine for prevention of botulism. Biochimie 82:955–960.
18. Wein LM, Liu Y (2003) Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Nat Acad Sci USA 102:9984–9989.
19. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432:925–929.
20. Chen S, Barbieri JT (2011) Association of Botulinum Neurotoxin Serotype A Light Chain with Plasma Membrane bound SNAP-25. J Biol Chem 286:15067–15072.
21. Tang J, Park JG, Millard CB, Schmidt JJ, Pang Y-P (2007) Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PLoS ONE 2:e761.
Identification of SMNPI against BoNT/A in Mice

22. Burnett JC, Schmidt JJ, McGrath CF, Nguyen TL, Hermone AR, et al. (2005) Conformational sampling of the botulinum neurotoxin A light chain: implications for inhibitor binding. Bioorg Med Chem 13:333–341.

23. Burnett JC, Wang C, Nuss JE, Nguyen TL, Hermone AR, et al. (2009) Pharmacophore-guided lead optimization: rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype A metalloprotease. Bioorg Med Chem Lett 19:5011–5013.

24. Roxas-Duncan V, Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, et al. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA104:2602–2607.

25. Lai H, Feng M, Roxas-Duncan V, Dakshanamurthy S, Smith LA, et al. (2009) Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition. Arch Biochem Biophys 491:75–84.

26. Boldt GE, Kennedy JP, Janda KD (2006) Identification of a potent 1botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett 8:1729–1732.

27. Capkova K, Hixon MS, Pellett S, Barbieri JT, Johnson EA, et al. (2010) Benzylidine cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A’s zinc endopeptidase. Bioorg Med Chem Lett 20:206–208.

28. Park JG, Sill PC, Makhi EF, Garcia-Sosa AT, Millard CB, et al. (2006) Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin type A. Bioorg Med Chem 14:395–408.

29. Bing L, Pai R, Cardinale SG, Butler MM, Prent NP, et al. (2010) Synthesis and Biological Evaluation of Botulinum Neurotoxin A Protease Inhibitors. J Med Chem 53:2564–2576.

30. Hermone AR, Burnett JC, Nuss JE, Tressler LE, Nguyen TL, et al. (2008) Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. Chem Med Chem 3:1905–1912.

31. Pang YP, Davie J, Wang S, Park JG, Nambiar MP, et al. (2010) small-molecules showing significant protection of mice against botulinum neurotoxin A. PLoS ONE 5:e10129.

32. Burnett JC, Li V, Pai R, Cardinale SG, Butler MM, et al. (2010) Analysis of botulinum neurotoxin serotype A metalloprotease inhibitors: analogs of a chemotype for therapeutic development in the context of a three-zone pharmacophore. Open Access Bioinformatics 2:11–18.

33. Pang YP, Vummethala A, Mishra RR, Park JG, Wang S, et al. (2009) Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PLoS ONE 4:e7730.

34. Boldt GE, Eubanks LM, Janda KD (2006) Identification of a botulinum neurotoxin A protease displaying efficacy in cellular model. Chem Commun (Cambridge) 29:3063–3065.

35. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, et al. (2007) Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small-molecule that is active in primary neurons. J Biol Chem 282:5004–5014.

36. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, et al. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA104:2602–2607.

37. Ruthel G, Burnett JC, Nuss JE, Wanner LM, Tressler LE, et al. (2011) Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors. Toxins 3:207–217

38. Singh P, Singh MK, Chauhan V, Gupta P, Dhakel RK (2011) Prevention of aggregation and autocatalysis for sustaining biological activity of recombinant BoNT/A-LC upon long-term storage. Protein Pept Lett 18:1177–1187.

39. Ferrari G, Maquilin R, Kozaki S, Seagar M, Leveque C (2003) Synaptic vesicle chips to assay botulinum neurotoxins. Biochem J 391:659–666.

40. Silvaggi NR, Wilson D, Tzepori S, Allen KN (2006) Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitor peptide complex. Biochemistry 47:5736–5745.

41. Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzepori S, et al. (2007) Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol 14:533–542.

42. Kumaran D, Rawat R, Ludovic ML, Ahmed SA, Swanianathan S (2008) Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin type A. J Biol Chem 283:18883–18891.

43. Kumaran D, Rawat R, Ahmed SA, Swanianathan S (2008) Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog 4: e1000165

44. Rao BG (2005) Recent developments in the design of specific Matrix Metalloprotease inhibitors aided by structural and computational studies. Curr Pharm Des 11:395–322.

45. Suzuki T, Miyata N (2005) Non-hydroxamate histone deacetylase inhibitors. Curr Med Chem 12:2867–2880.

46. Helmuth L (2000) Neuroscience: an antibiotic to treat Alzheimer’s? Science 290:1273–1274.

47. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (Clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer Disease, a pilot phase 2 clinical trial. ArchNeuro 60:1685–1691.

48. Zhou JH, Zhang, Gu P, Margolick JB, Yin D, et al. (2009) Cancer stem/ Progenitor cell active compounds 8-quinolinol in combination with paclitaxel achieves a improved cure of breast cancer in mouse model. Breast Cancer Res Treat 115:269–277.

49. Adler M, Dintener RE, Wannenacher RV (1997) Protection by the heavy metal chelator N,N,N’,N’-tetrakis (2-pyridylmethyl)ethylenediamine (TPEF) against the lethal action of botulinum neurotoxin A and B. Toxicon 31:1089–1100.

50. Chen S, Barbieri JT (2006) Unique substrate recognition by botulinum neurotoxin serotypes A and E. J Biol Chem 281:10906–10911.

51. Chen S, Barbieri JT (2007) Multiple pocket recognition of SNAP-25 by botulinum neurotoxin serotype E. J Biol Chem 282:25540–25547.

52. Shuowei C, Lindo P, Park JB, Vasa K, Singh BR (2010) The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity. Toxicon 55:818–826.

53. Thompson AA, Jiao GS, Kim S, Thai A, Gregor-Hernandez L, et al. (2011) Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the C. botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. Biochem 50:4019–4028.

54. McGovern SL, Caselli E, Grigoriou N, Shoichet BK (2002) A Common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45:1712–1722.

55. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr (1984) Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 150:407–412.